Plexin domain containing 2 (PLXDC2) is expressed on the surface of several cell types, such as macrophages, dendritic or epithelial cells. Its activation reduces oxidative stress and rebalances the immune response and decreases inflammation. Its activation has been seen to improve disease severity in models of rheumatoid arthritis, while its blockade or loss exacerbates the severity of dextran sulfate sodium (DSS)-induced colitis. Researchers hence tested the PLXDC2 agonist PX-04 (Landos Biopharma Inc.) in a DSS-induced murine model of colitis.